Does Blue Cross Blue Shield of North Carolina Cover Forteo?

What Is Forteo and Why Does It Require Special Coverage Review?

Forteo is a synthetic form of human parathyroid hormone (PTH 1-34), approved by the FDA in 2002 for postmenopausal women with osteoporosis at high fracture risk, men with primary or hypogonadal osteoporosis, and men and women with glucocorticoid-induced osteoporosis [1]. It works differently from antiresorptive agents like bisphosphonates: rather than simply slowing bone breakdown, it actively stimulates new bone formation.

Why Specialty Tier Placement Matters

Because Forteo requires refrigerated storage and is self-injected daily, most payers classify it as a specialty drug. BCBS NC plans typically route specialty drugs through a designated specialty pharmacy (often Walgreens Specialty, CVS Specialty, or a BCBS-contracted partner) rather than a retail counter. That routing affects your copay and the dispensing workflow.

Specialty tier cost-sharing under BCBS NC commercial plans commonly runs 25-33% coinsurance after the deductible, which on a drug with a wholesale acquisition cost near $3,500 per month translates to roughly $875-$1,155 per fill before any assistance programs. The specific dollar amount varies by your individual plan document.

The FDA Black Box Warning and Its Effect on Coverage

Forteo carries an FDA black box warning about osteosarcoma risk observed in rat studies at high doses [1]. Because of this, the FDA label restricts lifetime use to no more than 2 years. BCBS NC PA criteria universally reflect this limit. If you have already used 24 months of teriparatide on any prior policy, a new authorization is very unlikely to be approved.

How Does BCBS NC Determine Forteo Coverage Eligibility?

Prior authorization for Forteo on BCBS NC plans is evaluated against clinical criteria that mirror guidance from the Endocrine Society's 2019 Pharmacological Management of Osteoporosis guideline [2] and the American Association of Clinical Endocrinology (AACE) 2020 Clinical Practice Guidelines for Diagnosis and Treatment of Postmenopausal Osteoporosis [3].

Standard Prior Authorization Criteria

BCBS NC PA reviewers typically require documentation of all of the following:

1. A confirmed diagnosis of osteoporosis based on dual-energy X-ray absorptiometry (DXA), with a T-score at or below -2.5 at the lumbar spine, femoral neck, or total hip.
2. High fracture risk, defined by a prior fragility fracture or a FRAX 10-year major osteoporotic fracture probability at or above 20%, or hip fracture probability at or above 3% [3].
3. Trial and failure of, or a documented medical contraindication to, at least one antiresorptive agent. Alendronate, risedronate, ibandronate, and zoledronic acid are the agents most commonly referenced in step-therapy requirements.
4. Prescriber attestation that the patient has no personal or family history of bone cancer, Paget's disease, or prior radiation therapy to the skeleton.
5. A drug quantity limit consistent with the FDA label: 28-day supplies (one prefilled pen), renewable for up to 24 months total.

Step Therapy and Bisphosphonate Failures

Step therapy requirements are the most frequent reason an initial Forteo request is denied. BCBS NC plans generally require documented use of a generic bisphosphonate for a minimum of 6-12 months before approving an anabolic agent. The clinical rationale is supported by data: in the VERO trial (N=1,360), teriparatide 20 mcg daily reduced new vertebral fractures by 56% compared with risedronate over 24 months [4], a statistically significant benefit. However, that superiority does not eliminate payer requirements to try lower-cost agents first.

Exceptions to bisphosphonate step therapy are granted when a patient has documented upper gastrointestinal disease precluding oral bisphosphonates, renal impairment (eGFR <35 mL/min/1.73m2 is the most commonly cited threshold), or a history of atypical femur fracture or osteonecrosis of the jaw attributable to prior antiresorptive use.

Medicare Advantage and State Health Plan Differences

BCBS NC administers several distinct plan types, and coverage criteria differ across them.

Commercial fully-insured plans: Criteria described above apply. The state's 2021 step-therapy reform law (Session Law 2021-154) requires that BCBS NC allow step-therapy override requests when a clinician documents that the required drug is contraindicated or clinically inappropriate for the specific patient.

State Health Plan (for NC state employees): The BCBS NC State Health Plan uses a separate formulary managed through Navitus Health Solutions as the pharmacy benefit manager for plan year 2025. Forteo and its teriparatide biosimilar Bonsity both appear on the specialty tier. The State Health Plan's PA criteria closely parallel the commercial criteria above, with a documented step-therapy requirement.

Medicare Advantage plans: BCBS NC Medicare Advantage products (Blue Medicare HMO, Blue Medicare PPO) must comply with CMS coverage rules under 42 CFR Part 422. CMS does not mandate coverage of any specific osteoporosis drug, but it requires that plans cover at least two drugs in each therapeutic category. Teriparatide typically sits alongside abaloparatide (Tymlos) and romosozumab (Evenity) as anabolic agent options. PA is required on all three.

How to Submit a Prior Authorization Request for Forteo Through BCBS NC

The following step-by-step framework reflects the current BCBS NC provider portal process and is reviewed by the HealthRX medical team for accuracy. Individual plan timelines may vary.

Step 1: Confirm Your Specific Plan's Formulary

Before submitting anything, log into the BCBS NC member portal at bcbsnc.com or call the Member Services number on the back of your insurance card. Confirm that Forteo or its biosimilar Bonsity appears on your formulary and note the exact prior authorization fax number for pharmacy benefits. Submitting to the wrong department is the most common delay point.

Step 2: Gather Required Clinical Documentation

Your prescriber will need to compile the following documents for the PA package:

• The most recent DXA report with T-scores listed for lumbar spine and hip
• FRAX calculation printout (available free at sheffield.ac.uk/FRAX)
• Radiology or clinical notes documenting any prior fragility fractures
• Pharmacy dispensing records or chart notes confirming prior bisphosphonate use and the reason for discontinuation or inadequate response
• A completed BCBS NC specialty drug prior authorization form (available on the BCBS NC provider portal)
• The prescribing clinician's DEA number and NPI

Step 3: Submit via the Provider Portal or Fax

BCBS NC accepts PA submissions through the Availity provider portal, which BCBS NC uses for electronic transactions. Turnaround for standard review is typically 3-5 business days. Urgent reviews (when the patient has an acute clinical need) must be completed within 72 hours under North Carolina insurance law.

Step 4: Coordinate With the Specialty Pharmacy

Once approved, BCBS NC will typically require the prescription to be routed to a contracted specialty pharmacy. The specialty pharmacy conducts its own benefit investigation, ships the medication refrigerated, and often provides injection training resources.

What Happens If BCBS NC Denies Your Forteo Claim?

Denial is not the end of the process. About one in three specialty drug initial requests is denied on the first submission. A well-constructed appeal substantially changes outcomes.

First-Level Internal Appeal

You or your prescriber can request an internal appeal within 60 days of receiving the denial notice. The appeal letter should address the specific denial reason (usually step-therapy non-completion or insufficient fracture risk documentation) and include any additional clinical records, peer-reviewed literature supporting teriparatide use in your clinical scenario, and a letter of medical necessity from the prescribing physician.

The Endocrine Society's position statement notes that "for patients with very high fracture risk, anabolic therapy is appropriate as initial treatment," which directly counters step-therapy denials in qualifying patients [2]. Including the specific guideline citation strengthens the appeal.

External Review

North Carolina law entitles you to an independent external review if the internal appeal is denied and the denial involves a medical judgment. External reviews are conducted by an Independent Review Organization (IRO) not affiliated with BCBS NC. In North Carolina, external review requests must be filed within 60 days of the final internal denial. Studies of external review outcomes across payers find that patients win roughly 40-45% of external reviews involving specialty drugs [5].

Step-Therapy Override Under NC Law

Session Law 2021-154, North Carolina's step-therapy reform, requires BCBS NC to grant a step-therapy override within 5 business days (1 business day for urgent requests) when a prescriber documents that the required step-therapy drug:

• Is contraindicated
• Is expected to cause an adverse reaction
• Is expected to be clinically ineffective based on the patient's history
• Has already been tried and failed

This law provides meaningful recourse when a patient cannot tolerate bisphosphonates due to GI side effects, renal disease, or prior atypical fractures.

How Much Will Forteo Cost With BCBS NC Coverage?

Cost depends on three variables: your plan tier structure, your deductible status, and whether you have met any out-of-pocket maximum.

Estimated Monthly Cost Scenarios

For a patient on a BCBS NC commercial plan with a Tier 4 specialty drug coinsurance of 30% and a $500 deductible already met, a monthly Forteo supply at a wholesale acquisition cost of approximately $3,500 would generate roughly $1,050 out-of-pocket. The teriparatide biosimilar Bonsity (launched 2022 by Teva) carries a lower list price and the same clinical data, since FDA biosimilar approval requires demonstration of no clinically meaningful differences from the reference product [6].

Biosimilar Substitution and Cost Savings

North Carolina pharmacy law permits biosimilar substitution at the pharmacy level when the FDA has designated the biosimilar as interchangeable. Bonsity received FDA biosimilar designation but not interchangeable designation as of early 2025, meaning your pharmacist cannot automatically substitute it without prescriber authorization. Ask your doctor to write the prescription for teriparatide (generic) or specifically for Bonsity if cost is a concern.

Lilly Cares Foundation Patient Assistance

Eli Lilly's Lilly Cares Foundation offers free Forteo for patients who meet income eligibility criteria (typically household income at or below 400% of the federal poverty level and no adequate insurance coverage). The program can also provide copay assistance cards for commercially insured patients. Contact Lilly Cares at 1-800-545-5979 or visit lillycares.com.

Clinical Evidence Supporting Forteo for Osteoporosis

BCBS NC reviewers and their medical directors evaluate PA requests against published evidence. Understanding the key trials helps clinicians write stronger letters of medical necessity.

Fracture Prevention Data

The key Fracture Prevention Trial (FPT), which enrolled 1,637 postmenopausal women, showed that teriparatide 20 mcg/day reduced new vertebral fractures by 65% and nonvertebral fragility fractures by 53% compared with placebo over a median of 21 months [7]. These numbers are cited in the FDA label and in every major osteoporosis guideline.

The VERO trial (N=1,360) found that teriparatide reduced new vertebral fractures by 56% compared directly with risedronate 35 mg/week at 24 months (P<0.0001) [4]. Clinical superiority over an oral bisphosphonate in a head-to-head trial is a strong argument for use in patients who have already tried and failed antiresorptive therapy.

Bone Mineral Density Gains

In a 2019 systematic review published in Osteoporosis International covering 27 randomized controlled trials, teriparatide produced mean lumbar spine BMD gains of 8.6-13.0% over 18-24 months, larger than any antiresorptive comparator in the same dataset [8]. These gains are partially retained when patients transition to antiresorptive therapy (alendronate, denosumab, or zoledronic acid) after completing the teriparatide course.

Post-Teriparatide Sequential Therapy

The SHOTZ trial and follow-on data from the FPT both indicate that BMD gains from teriparatide are substantially reversed if no antiresorptive agent is prescribed after discontinuation. This is clinically significant: BCBS NC authorization for Forteo will typically include a care plan note that sequential therapy is expected. Prescribers should document the intended post-teriparatide regimen in the PA request.

Alternatives to Forteo That BCBS NC May Cover at a Lower Tier

If prior authorization for Forteo is denied or the cost remains prohibitive, several alternatives may be covered at a lower tier or with fewer PA barriers.

Antiresorptive Agents

Alendronate (generic, 70 mg weekly) is the most commonly covered first-line agent and is typically placed on Tier 1 or Tier 2 with a copay of $10 or less on most BCBS NC plans. Risedronate (generic), ibandronate (generic), and zoledronic acid (generic infusion) are also generally well-covered.

Denosumab (Prolia, 60 mg subcutaneous every 6 months) is a RANK-L inhibitor with demonstrated vertebral fracture reduction of 68% at 3 years in the FREEDOM trial (N=7,808) [9]. Denosumab sits at Tier 3 or specialty tier on most BCBS NC plans and also requires PA, but the clinical threshold for approval is lower than for anabolic agents.

Other Anabolic Agents

Abaloparatide (Tymlos, 80 mcg/day) is a PTH-related protein analogue with a similar mechanism to teriparatide. The ACTIVE trial (N=2,463) showed abaloparatide reduced vertebral fractures by 86% compared with placebo over 18 months [10]. BCBS NC coverage criteria for abaloparatide mirror those for teriparatide. Romosozumab (Evenity, 210 mg monthly for 12 months) is a sclerostin inhibitor with an anabolic and antiresorptive dual mechanism, but it carries a black box warning for cardiovascular events and is restricted by PA criteria requiring no prior myocardial infarction or stroke.

Key Questions to Ask Your Doctor Before Submitting a Forteo PA

Preparing for the prior authorization process improves approval rates. Bring these specific questions to your prescriber visit:

1. Is my T-score below -2.5, and has this been measured within the past 24 months?
2. Do I have a documented fragility fracture in my chart, or does my FRAX score exceed the 20%/3% thresholds?
3. Have prior bisphosphonate trials been documented in my medical record with the reason for discontinuation?
4. Is there a medical contraindication to bisphosphonates (GI disease, low eGFR, prior atypical fracture) that should be noted in the PA?
5. What specialty pharmacy does my BCBS NC plan require for Forteo?
6. Should we prescribe teriparatide (generic/Bonsity) instead of brand Forteo to reduce cost?
7. What sequential antiresorptive therapy will you prescribe after my teriparatide course ends?